Gene’s future in genetics at Novo Nordisk was written in the stars. Of course, his name is Gene. His childhood interest in fishkeeping eventually led him to learn about biological drivers at university. And not just any university, but the University of Toronto, that made a significant contribution to the isolation of insulin. And when he decided to leverage his scientific skills, interests, and knowledge to impact human health, it led him to none other than Novo Nordisk.

The rest is history… in the making.

Gene is excited about the potential of gene therapies. And he knows that with our resources, his colleagues’ expertise and the partnerships we’re building in and outside of the company, major advancements in the treatment of obesity and diabetes are on the horizon.

“I think we’re on the cusp of a health revolution where genetic medicines are going to fill the market and make a real difference to patients suffering from chronic diseases. No other organization has done more for hormonal or protein and peptide-related medicine than Novo Nordisk. There has been a vested interest in bringing in the newest technology and science, building on the innovation and expertise that we’ve cultivated for the past 100 years. Within genetic medicine, we’re inserting and deleting. We’re embracing a wide array of tools. And we’re partnering with outside groups, from biotechs to academics, to cultivate the best ideas. That’s how we’re going to bring about the next generation of therapies for patients.”

Development at Novo Nordisk extends beyond our products, especially in the R&D space, as Gene is experiencing first hand. He explains “Our people are at the heart of what we do, and our people are at the core of our innovation.. And it means big things for him and his colleagues.